U

.S. regulators have approved the first drug aimed at women with advanced breast cancer caused by an inherited flawed gene.

The Food and Drug Administration on Friday approved AstraZeneca PLC’s Lynparza for patients with inherited BRCA gene mutations who have undergone chemotherapy.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • I wonder if this drug might be adapted to be used as a pre-emptive for those who have the BRCA gene but have not yet developed breast cancer, stopping it in it’s tracks before it ever shows up! That would certainly be cause for celebration!!

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.